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Abstract
Probiotics are defined as live microorganisms that, when administered in adequate 
amounts, confer a health benefit on the host. Probiotics have been used to directly modify 
the resident oral microbiome and proposed to modulate immune responses. In dentistry, 
probiotics have been employed as useful adjuncts for the reduction of caries develop-
ment, suppressing oral Candida infection and controlling halitosis. Plaque-induced gin-
givitis is a gingival inflammation caused by the adherent bacterial biofilm around teeth. 
Gingivitis and periodontitis are considered to be a continuum of the same inflammatory 
process, although many gingivitis lesions do not progress to periodontitis. Periodontitis 
is an inflammatory process that affects the attachment structures of teeth. It constitutes a 
second cause of tooth loss worldwide. Conventional treatment modalities of periodontal 
disease include non-surgical and/or surgical management, with an emphasis on mechan-
ical debridement. However, mechanical debridement as a sole therapy is not always 
effective to improve clinical parameters. A growing number of studies support probiotic 
therapy to prevent or treat gingivitis and periodontitis. Oral administration of probiotics 
is an effective adjunct in reducing pathogenic bacteria and improving clinical signs of 
disease. Probiotics may serve as adjunct or replacement therapy substitute antibiotics in 
managing human periodontal infections in future.
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1. Introduction
In order to speak about probiotics, we have to go back to the twentieth century when the Russian 
scientist Elie Metchnikoff postulated the theory about the influence of gastrointestinal micro 
biota (gut flora) over ageing. In 1908, this Nobel Prize winner attached the  longevity of some 
Balkans towns to the frequent consumption of fermented dairy, containing Lactobacillus, which 
reduced the toxins produced by intestinal bacteria, promoting health and prolonging life [1].
© 2017 The Author(s). Licensee InTech. This chapt r is distributed under the terms of the Creative Comm s
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distribution, and reproduction in any medium, provided the original work is properly cited.
The discovery of Lactic Acid Bacteria (LAB) in the middle of the nineteenth century confirmed 
the interest in microorganism and since then many people have concluded that dairy fer-
mented by lactobacillales provide numerous benefits to our health [2].
For a long time, microorganisms have been responsible for the production of numerous foods 
and drinks and also have had an important impact on human health. The discovery of a sym-
biotic relationship between bacteria and humans awoke the curiosity of seeing the bacteria as 
potentially beneficial rather than pathogenic [2].
Lilly and Stillwell coined the term “probiotics” first definition in 1965 as: “Living microorgan-
isms that confer a benefit to the host’s health when given in adequate amounts” [3]. The term 
“prebiotic” was defined as “a non-digestible food ingredient that beneficially affects the host 
by selectively stimulating the growth and/or activity of one or a limited number of bacteria in 
the colon, and thus improves host health” by Gibson and Roberfroid [4].
Symbiotic is the relationship between probiotics and prebiotics, which benefits the host by 
increasing the survival and implantation of live microorganisms from dietary supplements 
in the gastrointestinal system [5]. This has not been deeply studied, but it could increase 
bacteria potential to develop their function in the colon because symbiotic products could 
increase the survival of probiotic in their intestinal transit phase. Also, a synergic effect has 
been described. Prebiotics contribute to the installation of a specific bacterial flora with ben-
eficial effects on health because they stimulate the growth of specific strains [6].
Nowadays the term probiotic has evolved and is now described as “living microorganisms, 
mostly bacteria, non-pathogenic, used as nutritional supplement, which after being ingested 
in the right amount, improve the intestinal microbial balance and cause beneficial effects on 
the health of those who ingest them” [7]. They are considered safe for human health [8]. 
Since the 1980s scientific investigation about healthy properties of ingesting probiotics has 
increased considerably, which boosted their use and led to their appearance in clinical prac-
tice as treatment for diseases such as chronic diarrhea, immune regulation, allergies, inflam-
matory bowel disease, constipation, lactose intolerance and lipid intolerance [9]. Lately there 
is big concern regarding the use of probiotics to treat oral infections like dental cavities (car-
ies) and periodontal diseases. However, available information about the effects of probiotics 
on periodontal health is still minimal [10].
Chronic oral infections in soft tissues cause inflammatory alterations releasing pro-inflamma-
tory substances such as cytokines, which through the circulatory system, access any area of 
the body, increasing the risk of muscular, digestive and cardiovascular problems, premature 
birth, diabetes and sports injuries. Hence, the treatment of chronic oral diseases and the main-
tenance of oral health should be considered as an asset in the prevention of systemic problems 
for general health [11].
Periodontal diseases and dental cavities have high prevalence [12], and according to the World 
Health Organization, the majority of children have signs of gingivitis and among adults the initial 
stages of periodontal disease are highly prevalent [13]. Bacterial biofilm that forms in the hard and 
soft tissues of the oral cavity is considered the main etiological factor in most pathological conditions 
Insights into Various Aspects of Oral Health74
of the oral cavity. The accumulation of bacteria inside the biofilm, provided by a poor oral health, 
influences changes in the microbial community, leading to periodontal inflammation [14].
Several studies such as Gorbach and Goldin (1985) [15], Näse et al. (2001) [16], Grudianov et al. 
(2002) [17], Wei et al. [18], Von Bultzingslowen et al. [19], Hatakka et al. (2007) [20] have spoken 
about the relation between bacterial strains like Lactobacillus rhamnosus, Bifidobacterium spp, 
and Lactobacillus plantarum, which have a positive effect on tooth adhesion and their action 
against diseases such as dental cavities (caries) and yeast infection. In recent years, treatments 
of periodontal diseases have changed to an antibiotic or antimicrobial kind. Nonetheless, 
with the increased incidence of antibiotic resistance, probiotics may be a promising area of 
research in periodontal therapy [21]. Currently, there is a probiotic that can be used for oral 
hygiene, as it combats dental plaque, gingivitis and cariogenic bacteria through the patented 
combination of two strains of Lactobacillus reuteri. This is 100% natural due to its residence in 
the human gastrointestinal tract and production of an antibiotic substance of broad-spectrum 
called “reuterina”, which administrated in the right amount, causes the desired antimicrobial 
effect to keep the intestinal microbiota intact [11].
Increasingly, antibiotics become complex elements to manage in medical therapies due to the 
increment of bacterial resistance to them. However, inversely proportional, clinical studies 
have shown the positive effects in human health associated with the use of probiotics. This 
is the reason why the World Health Organization supports the use of probiotics as micro-
bial interference therapy. Consequently, the use of probiotics could be postulated as a useful 
alternative in the control of periodontal diseases, since it improves the conditions of the host, 
reducing periodontal pocket depth, inflammation, bleeding and halitosis.
2. Local mechanisms of probiotic action
Several mechanisms have been suggested to contribute to the probiotic action. Their effects at 
local level are mentioned as follows:
1. Production of lactic acid (a short chain fatty acid) can penetrate the bacterial membrane 
and acidify the cytoplasm by inhibiting the proliferation of Porphyromonas gingivalis, Strep-
tococcus mutans [22] and Prevotella intermedia [23]. Lactobacillus gasseri is a homofermentative 
bacteria (metabolism via glycolysis) that is able to produce large quantities of lactic acid.
2. Production of hydrogen peroxide can inhibit the growth of pathogenic bacteria [24–26]. 
Streptococcus sanguinis reduces the levels of Aggregatibacter actinomycetemcomitans (in 
about 45 times) and S. mutans.
3. Protein modification on the site of attachment, removal of aglutinina gp 340, which is 
necessary for the attachment of S. mutans [16].
4. Production of biosurfactants that prevent bacterial adhesion. Streptococcus mitis produces 
a biosurfactant that prevents adhesion of S. mutans and some periodontopathogenic bac-
teria to the tooth surface.
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5. Production of bacteriocins (cationic peptides synthesized on ribosomes with antimicro-
bial activity that have a narrow spectrum of action) [27–29].
(a) Salivaricin A and B: Bacteriocins produced by Streptococcus salivarius. Salivaricin 
decreases the proliferation of S. mutans and Streptococcus sobrinus in carious le-
sions. Salivaricin B inhibits the growth of Prevotella spp. and Micromonas micros 
in halitosis.
(b) Reuterin: Bacteriocin produced by L. reuteri, has antibacterial activity on bacterial 
Gram (+) and Gram (−), fungi (Candida albicans) and protozoa. Among them S. 
mutans and P. intermedia.
6. Production of inhibitory substances like bacteriocins: peptides synthesized on ribosomes 
with antimicrobial activity and broad spectrum of action.
7. Production of vitamins and other substances.
(a) Lactobacillus acidophilus can participate in the production of niacin, folic acid and 
vitamin B6.
(b) Bifidobacterium dentium increases the absorption of iron, zinc, calcium and 
magnesium.
(c) Streptococcus thermophilus synthesizes polysaccharides such as hyaluronic acid 
and produces urease.
8. Changes in the cellular envelope: Lactobacillus paracasei HL32 inhibits P. gingivalis to in-
duce a change in the cellular envelope [30].
9. Glucosiltransferasa enzyme inhibition. L. rhamnosus inhibits the glycosyl-transferase en-
zyme by reducing the synthesis of glucans in the formation of the biofilm.
10. Anti-oxidant effect.
(a) Bifidobacterium longum has anti-oxidant effect by inhibiting the formation of lino-
lenic acid in the form of hydrogen peroxide.
(b) Lactobacillus brevis decreases the levels of nitric oxide synthetases (NOS).
11. Ingested probiotics can impact resident communities through trophic interactions, a di-
rect alteration in fitness or an indirect alteration in fitness through altered production of 
host-derived molecules [31]. The major changes of gastrointestinal microbiome occur in 
stomach and small intestine. These are important not only quantitatively; they may also 
alter the relative abundance of major phyla [32–35].
3. Systemic mechanisms of probiotic action
The systemic mechanisms of probiotic action are associated with its effect on immune 
response. In past years, there have been an increasing number of studies linking gut health 
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with several chronic diseases. In order to understand these mechanisms, it is necessary to 
review this literature.
3.1. Use of probiotics in medicine
Clinical studies have demonstrated the clinical potential of probiotic against many diseases. 
However, generalizations concerning the potential health benefits of probiotic should not be 
made because its effects are strain-specific [36]. Probiotics have been used in some conditions, 
such as:
3.1.1. Atopic dermatitis
Atopic dermatitis is a chronically relapsing skin disease that occurs most commonly during 
early infancy and childhood. It is associated with allergen sensitization, recurrent skin infec-
tions and abnormalities in skin barriers function [37]. Foolad et al. published a meta-analysis 
study aimed to find evidence about the effect of probiotics in children with atopic dermatitis 
[38]. They concluded that the use of probiotics, specifically L. rhamnosus GG [39], showed 
to be effective in mothers and infants in preventing the development and reducing severity 
of atopic dermatitis [38]. In adult patients, the use of L. salivarius LS01 [40] and a combina-
tion of L. salivarius LS01 with Bifidobacterium breve BR03 [41] were associated with significant 
improvement of clinical manifestations of atopic dermatitis.
3.1.2. Antibiotic-associated diarrhea
Diarrhea is a common side effect of antibiotic use. It can be classified as Clostridium-associated 
antibiotic diarrhea or non-Clostridium difficile-associated antibiotic diarrhea. The first one is 
benign. In contrast, the second one refers to a wide spectrum of diarrhea illnesses caused by 
the toxins produced by C. difficile, including cases of severe colitis with or without the presence 
of pseudomembranes [42]. A series of meta-analysis concluded that probiotics significantly 
reduce the risk of antibiotic-associated diarrhea in children [43] and adult patients [44]. It was 
associated with the use of L. rhamnosus GG, B. lactis and S. thermophiles [43]. S. boulardii was 
reported to be effective in C. difficile disease [45, 46].
3.1.3. Irritable bowel syndrome (IBS)
IBS is defined as an abdominal discomfort or pain associated with altered bowel habits for at least 
3 days in the previous 3 months, with the absence of organic disease [42]. A meta-analysis demon-
strated that, compared with placebo, the use L. rhamnosus GG was associated with a significantly 
higher rate of treatment responders in the overall population with abdominal pain-related func-
tional gastrointestinal disorders and in the irritable bowel syndrome patients [47].
3.1.4. Inflammatory bowel disease (IBD)
IBD consists of two disorders: ulcerative colitis (UC) and Crohn’s disease (CD). The gut 
mucosa suffers a chronic, uncontrolled inflammation. CD is characterized by focal transmural 
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inflammatory lesions and ulcerations that can be present anywhere in the gastrointestinal 
tract. UC is more superficial and limited to colon.
A meta-analysis concluded that remission rates in patients with active UC were significantly 
higher in patients who were treated with probiotics, specifically, VSL#3 (a combination of 
probiotics containing B. breve, B. longum, Bifidobacterium infantis, L. acidophilus, L. plantarum, 
L. paracasei, L. bulgaricus and S. thermophiles) [48].
3.1.5. Helicobacter pylori
Probiotics do not eradicate H. pylori, but they can diminish the levels of this bacterium in the 
stomach. In association with antibiotic treatments, some probiotics increased eradication rates 
and/or decreased adverse effects due to the antibiotics [49].
3.1.6. Necrotizing enterocolitis
It is a severe condition occurring especially in preterm infants. A Cochrane review concluded 
in 2011 that enteral supplementation with probiotics prevents sever necrotizing enterocolitis 
in preterm infants [50].
3.1.7. Hypocholesterolemic treatment
The combinations of prebiotics and probiotics such as bifidobacteria and FOS, lactobacilli and 
lactitol, and bifidobacteria and galactooligosacharides were used in trials and have shown 
promising results in hypocholesterolemic effect [51].
3.1.8. Radiation enteritis
Pelvic malignancies are commonly treated with radiation therapy. Chronic gastrointestinal 
side effects occur in over 30% of patients [42]. A meta-analysis concluded that probiotic treat-
ment with Lactobacillus spp could prevent chemotherapy and radiation enteritis-induced diar-
rhea in patients with pelvic malignancies [52].
3.2. Probiotic effect on immune responses
Probiotics help maintain gut immune homeostasis by modulating immune response, enhancing 
epithelial barrier function and inhibiting pathogen growth. Probiotic interaction with mucosal 
immune system is through the same pathways as commensal bacteria. Its effect appears to be 
more immune regulating than immune activating [37].
Probiotics modulate epithelial barrier function through interactions with Toll-like receptor 
(TLR)-2 [53]. The initiation of TLRs signalling regulates synthesis of pro-inflammatory cyto-
kines, chemokines and antimicrobial peptides, recruitment of B cells and production of IgA 
[54]. Probiotics have been shown to suppress systemic inflammatory response, modulating epi-
thelial signal transduction pathways and cytokine production [55]. For example, Lactobacillus 
johnsonni N6.2 up-regulated type-1 interferon and IFN regulators Stat1 and IRF7 in a TLR-9 
dependent way, in rats [56].
Insights into Various Aspects of Oral Health78
Several strains of lactic acid bacteria induce in vitro release of pro-inflammatory cytokines 
TNF-α and IL-6, reflecting stimulation of nonspecific immunity [57]. L. acidophilus Lal enhances 
phagocytosis in humans [58]. L. casei Shirota can enhance natural killer cell activity in vivo and 
in vitro in humans [59]. However, there are some bacteria that can decrease pro-inflammatory 
molecules. For example, L. brevis CD2 decreases inflammatory markers in saliva from patients 
with periodontal disease, including prostaglandin E2 (PGE2) [60]. Also, it was reported that 
probiotics, specifically, L. reuteri ATCC PTA 5289 decreased in CGF levels of TNF-α and IL-1β 
in patients with chronic periodontitis [61]. Streptococcus cristatus, S. salivarius, S. mitis and S. 
sanguinis may decrease the release of IL-8 by the epithelial cells stimulated with Fusobacterium 
nucleatum and A. actinomycetemcomitans [62–64].
Some specific strains generate an effect on maturation of dendritic cells (DC). DC has a central 
role in directing the T cell response. They can change to T helper cell (Th) 1, Th2, Th17 and 
T regulatory cells (Treg) [65]. Certain bacterial strains induce the production of Th polar-
izing key cytokines by DCs, such as IL-10, IL-12 and IL-23 [66, 67]. Also, some Lactobacillus 
strains have been shown to stimulate Th1 cytokine production while others have increased 
Th2 responses or induced a mixed Th1/Th2 response [37]. An example of this is the use of a 
combination of L. salivarius LS01 and Bifidobacterium breve BR03 in treatment of atopic derma-
titis. This probiotic mix generated a significant reduction in microbial translocation, immune 
activation, improved Th17/Treg cell and Th1/Th2 [41]. Intervention with B. bifidum, L. acidophi-
lus, L. casei and L. salivarius effectively reduced signs of atopic dermatitis and serum cytokines 
interleukin (IL-5, IL-6, IFN-γ and serum IgE) [68]. L. rhamnosus GG could up-regulate IFN-γ 
and IL-10 in infants with cow’s milk allergy or with IgE-associated dermatitis [69]. The use 
of Lactobacillus delbruekii and Lactobacillus fermentum significantly reduced IL-6 concentration 
and expression of TNF-α and NFκB in colon of patients with ulcerative colitis [70]. L. brevis 
CD2 decreased IFN-γ levels in saliva [60]. L. reuteri ATCC PTA 5289 decreased in CGF levels 
of IL-17 in patients with chronic periodontitis [61].
Anti-inflammatory effect of probiotics has been associated with Treg. For example, oral admin-
istration of L. casei alleviated colitis and increased the suppressive function of Treg of colon 
lamina propia. Consumption of B. infantis drives the generation of Treg cells, which attenuate 
nuclear factor kappa B (NFκB) activation induced by LPS of Salmonella typhimurium [71].
There is evidence of the effect of some probiotics on matrix metalloproteinases (MMP). They 
represent a family of human zinc-dependent endopeptidases [65]. L. brevis CD2 decreased 
MMP in saliva [60]. L. reuteri DSM 17938 + ATCC PTA 5289 decreased GCF MMP-8 and 
increased tissue inhibitors of matrix metalloproteinase (TIMP)-1 levels in patients with peri-
odontitis [72].
Current studies also mentioned the role of probiotics in modulation of cell signal transduc-
tion pathways, specifically NFκB, which monitors the inflammatory response in the host [73]. 
L. reuteri inhibited inhibitory κB (IκB) degradation and IL-8 expression in TNF-α induced T84 
cells and NFκB translocation to the nucleus in HeLa cells [74]. In the same way, L. rhamnosus 
GG diminished nucleus translocation of NFκB, restored decreased cytoplasmic IκB and limited 
IL-8 secretion in Caco-2 cell model [75]. These actions impede the stimulation of transcription 
of a series of pro-inflammatory genes such as the encode cytokines, chemokines and grow fac-
tors that modulate the proliferation of immune cells [76]. In bronchial epithelial cells cocultured 
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with S. salivarius K12, an immunosuppression was observed, coincident with the inhibition of 
activation of the NF-κB pathway.
Certain strains of Bifidobacteria, Lactobacilli, Escherichia coli, Propionibacterium, Bacillus and 
Saccharomyces influence gene expression of TLRs, NFκB and interleukins. In vitro, the interac-
tion of probiotics with antigen presenting cells results in downregulation of pro-inflamma-
tory genes and upregulation of anti-inflammatory genes [36].
4. Probiotics and gingivitis
The adherent bacterial biofilm around the teeth produces a gingival inflammation called plaque-
induced gingivitis [77]. It is the most common form of periodontal disease worldwide and plenty 
of data exist, from different countries and age groups, about the prevalence, extent and severity 
of gingivitis. Studies on population have shown that regardless of age, gender and race, gingi-
vitis is always associated with the level of oral hygiene [78]. Large-scale population studies on 
children, adolescents, adults and elderly people have reported very high prevalence of gingivi-
tis, ranging from 50 to 100% [79–82]. Gingivitis and periodontitis are regarded as a continuum of 
a same inflammatory process. However, it is necessary to point out that in many cases gingivitis 
does not progress to periodontitis [83, 84].
Once the teeth erupt, a bacterial biofilm immediately begins to form at their surfaces exposed 
to the oral cavity and in intimate contact with the gingival margin. The level of biofilm accumu-
lation, the virulence of the biofilm bacteria and the humoral and cellular immune responses to 
the biofilm microbiome are the factors that determine the severity of the periodontal disease 
[85]. Normally gingivitis in young subjects remains chronic for an extended period of time 
and does not cause any damage to the periodontal ligament or bone. Nevertheless, an altera-
tion of the balance between biofilm and host can originate a loss of periodontal attachment. 
Chronic and aggressive periodontitis start as gingivitis. However, the biological processes 
involved in the progression from gingivitis to periodontitis have been difficult to determine 
[86]. It is probable that the following elements are implicated in the disease progression to 
periodontitis: microbial dysbiosis, overgrowth of pathogenic bacteria, herpes virus reactiva-
tion, immune-system disruption and acquired and/or genetic susceptibility factors [87–89].
Mechanical removal of supragingival plaque is the most effective tool to prevent gingivi-
tis [90] but most individuals do not adequately control plaque accumulation and gingivitis 
continues to be prevalent. To overcome this hindrance, antimicrobial products in the form of 
dentifrices or mouthwashes have been tested for their adjunctive efficacy in reducing plaque 
and gingivitis.
Probiotic technology represents a breakthrough approach to maintain oral health by utilizing 
natural beneficial bacteria commonly found in healthy mouths to provide a natural defence 
against the bacteria thought to be harmful to teeth and gums [15]. Within dentistry, the previ-
ous studies with lactobacilli strains such as L. rhamnosus, L. casei, L. reuteri, or a Lactobacilli mix 
have revealed mixed results on oral microorganisms.
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Krasse et al. conducted one of the first clinical trial randomized double-blind placebo controlled. 
The principal aim of the study was to assess if the probiotic L. reuteri could be effective in the 
management of gingivitis and then to evaluate the influence of the probiotic on plaque and the 
lactobacilli population in the saliva. Fifty-nine patients with moderate to severe gingivitis were 
included and given either/or specific L. reuteri formulations (LR-1 or LR-2) at a dose of 2 × 108 
CFU/day, or a corresponding placebo. At baseline (day 0), they collected saliva to determine the 
lactobacilli and measured gingival index and plaque on two surfaces. They taught patients to 
brush and to floss their teeth carefully and the treatment began. The patients returned on day 
14 for final assessment of gingivitis and saliva and plaque were collected. Twenty patients were 
randomly given LR-1, 21 took LR-2 and 18 received inactive substances. The gingival index 
decreased evenly in all three groups (p < 0.0001). LR-1 only (not LR-2) improved more than 
placebo (p < 0.0001). Plaque index fell evenly in LR-1 (p < 0.05) and in LR-2 (p < 0.01) between 
day 0 and day 14 but without significant change in the inactive substance. On day 14, 65% of the 
patients in the LR-1 group were colonized with L. reuteri and 95% in the LR-2. L. reuteri reduce 
both gingivitis and plaque in patients with moderate to severe gingivitis [91].
Twetman et al. conducted a clinical trial randomized double-blind placebo controlled in 
patients with gingivitis (n = 42). The subjects were randomly assigned to one of three compa-
rable arms: Group A/P (n = 15) was given one active and one test substance gum daily, Group 
A/A (n = 14) received two active chewing gums and Group P/P (n = 13) two placebo gums. 
They used chewing gum (2 times a day for 10 min in the morning and evening) with L. reuteri 
(ATCC 55730 and ATCC PTA 5289, 1×108 CFU). They taught the patients to chew the gums 10 
min for 2 weeks and conducted bleeding on probing and GCF sampling at baseline and after 
1, 2 and 4 weeks. The levels of IL-1β, TNFα IL-6, IL-8 and IL-10 were measured using luminex 
technology and multiplex immunoassay kits. Bleeding on probing improved and GCF vol-
ume decreased in all groups during the chewing period. Still, the results were statistically 
different (p < 0.05) only in Groups A/P and A/A. TNFα and IL-8 levels decreased significantly 
(p < 0.05) in Group A/A compared with baseline after 1 and 2 weeks, respectively. They also 
observed a non-significant tendency to decrease in IL-1β during the chewing period. The 
levels of IL-6 and IL-10 remained unchanged in all groups after 1 and 3 weeks. The elemen-
tal basis of the probiotic approach to confront inflammation in the oral cavity could be the 
decrease of pro-inflammatory cytokines in GCF [92].
Staab et al. conducted a parallel-designed non-blinded study. Fifty volunteer students took 
part in this study. The test group took a probiotic drink (L. casei, 100 billion per 100 ml 
everyday); the control group did not drink any product. After 8 weeks, individual mechani-
cal plaque control was delayed for 96 h. Papilla bleeding index, interproximal plaque and 
Turesky plaque index were measured at baseline, after 8 weeks and again 96 h later. At the 
coincidence points, we collected GCF for evaluation of polymorphonuclear elastase, myelo-
peroxidase (MPO) and MMP-3. There was no difference in the interproximal plaque index 
and papillary bleeding between the groups. In the test group, the elastase activity and the 
amount of MMP-3 were significantly lower after the intake of the probiotic drink (p < 0.001 
and 0.016). A significant increase of MPO activity was noted in the control group; both groups 
had differences at the end of the survey (p = 0.014). According to the data, it is suggested that 
the probiotic milk drink has a beneficial effect on the gingival inflammation [93].
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Ierardo et al. conducted a clinical trial in patients with gingivitis: Test group (n = 21) con-
sumed chewing gum (3 times per day for 60 days) containing probiotic L. brevis. Control 
group was used for the laboratory variables (n = 16). Measurements were taken at baseline, 
30 and 60 days. It was concluded that L. brevis has anti-inflammatory effects showing clinical 
improvement. In addition, it allows to reduce the levels of immunoglobulin (Ig)-A [94].
Iniesta et al. conducted a clinical trial randomized double-blind in patients with gingivitis: 
Test Group (n = 20) obtained lozenges with L. reuteri (DSM-17938 and ATCC PTA 5289, 2 × 
108 CFU) for two periods of 12 weeks (with an intermediate period of 4 weeks without mea-
sures of hygiene). Microbiological and clinical differences and the pattern of colonization of 
L. reuteri were determined again. In conclusion, no significant changes occurred between and 
within the groups in the clinical variables. Total anaerobic counts in saliva after 4 weeks (p 
= 0.021) and counts of P. intermedia after 8 weeks (p = 0.030) decreased in the test group. In 
subgingival samples, P. gingivalis counts reduced significantly from baseline to 4 weeks (p = 
0.008). With PCR, the presence of L. reuteri ATCC-PTA-5289 was higher than L. reuteri DSM-
17938. The administration of L. reuteri in tablets reduced the number of selected periodontal 
pathogens in the subgingival microbiota, with no associated clinical impact [95].
Hallstrom et al. conducted a clinical trial randomized double-blind controlled in patients with 
gingivitis: Group test (n = 18) accepted lozenges of L. reuteri (ATCC 55730 and PTA TM9061, 
1×108 CFU), two times a day for 3 weeks (with a period of 2 weeks of experimental gingivitis). 
During the intervention periods, all the patients presented local plaque accumulation together 
with manifest gingivitis at the test sites. Both groups had an increase in the volume of GCF but 
it was statistically significant only in the placebo group (p < 0.05). The concentrations of IL1-β 
and IL-18 (p < 0.05) increased significantly, while IL-8 and macrophage inflammatory protein 
(MIP)1-β decreased (p < 0.05). No differences were found between test and inactive substance. 
Similarly, the microbial composition was not different between the groups. The plaque accu-
mulation, inflammatory reaction or composition of the biofilm did not seem to be significantly 
affected by the daily intake of probiotic lozenges during experimental gingivitis [96].
Karuppaia et al. conducted a randomized double-blind clinical trial in patients with gingivitis 
(aged 14–17 years): Test group (n = 108) used curd (clump of milk) 4 weeks. The control group 
(n = 108) excluded curd in their diet for 30 days. Clinical differences were found, the probiotic 
was efficacious in reducing the plaque index and gingival index [97].
Purunaik et al. conducted a clinical trial randomized double-blind placebo controlled in 
patients (aged 15–16 years) (n = 90) with gingivitis: Group A (n = 30) used chlorhexidine 
0.2%, Group B (n = 30) mouthwash of probiotic (L. acidophilus, L. rhamnosus, B. longum and 
Saccharomyces boulardii) (dose: 1.25 million mix, 2 times a day for 14 days), and Group C 
(n = 30) placebo (20 mL per day for 60 s.). It was found that both the chlorhexidine and 
the probiotic group can significantly reduce the plaque index (best chlorhexidine) and the 
gingival index (best probiotic) [98].
Lee et al. conducted a clinical trial randomized double-blind placebo controlled in patients 
(n = 34) with gingivitis: Group Test (n = 17) used lozenges of L. brevis (CD2, 1×109 CFU), three 
times per day × 2 weeks and Control group (n = 17) took placebo for the same period of time. 
It was found that probiotic reduced the bleeding on probing. There were no differences with 
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respect to the gingival index. The levels of NO (nitric oxid) increased in proportional form in 
the placebo group. The levels of MMP-8 and PGE-2 did not change [99].
Nadkerny et al. conducted a clinical trial randomized double-blind placebo controlled in 
three groups of patients (n = 45) with gingivitis: Group A (Test) used a mouthwash of pro-
biotic (L. acidophilus, L. rhamnosus, Lactibacillus sporogenes, B. longum and S. boulardii; n = 15), 
Group B (positive control) with chlorhexidine 0.2% (n = 15), and Group C (placebo: saline 
solution; n = 15) for 4 weeks. The mouthwash of probiotic and chlorhexidine was efficacious 
in reducing the plaque index and gingival index [100].
5. Probiotics and periodontitis
Periodontitis is an inflammatory process caused by an infection, and it implicates the inter-
action of biofilm and immuno-inflammatory response of host [101]. Its consequence is the 
destruction of attachment structures of teeth, or periodontium. There are three signs of disease: 
clinical attachment loss, alveolar bone resorption and presence of periodontal pocket [102].
Periodontitis constitutes the second cause of tooth loss worldwide [103–105]. Moreover, stud-
ies [106, 107] performed in South and Central America have shown that the prevalence of 
severe disease is high (>30%) in these populations.
Periodontitis is caused by complex subgingival microbial communities, which are in a dys-
biotic state [108]. However, a few bacteria in the subgingival biofilm have been associated 
with disease. Strong evidence concluded that P. gingivalis, A. actinomycetemcomitans and T. 
forsythia are periodontal pathogens [65]. Although the tooth-associated biofilm plays a role in 
the development of periodontitis, it is primarily the host inflammatory response that inflicts 
the irreversible damage on the periodontium [108]. T helper 1 and Th17 lymphocyte have 
been described in the pathogenesis of disease [65].
The aim of periodontal treatment is mechanical debridement of root surface. When peri-
odontal pathogens are effectively reduced after therapy and higher proportions of host-
compatible microorganisms is established, improvements in clinical parameters are achieved 
[109]. However, mechanical debridement as a sole therapy is not always effective to improve 
clinical parameters [110]. Therefore, systemic antibiotics were introduced as an adjunct to 
mechanical treatment [111]. This treatment modality eliminates the entire microbiota, irre-
spective of its pathogenicity. Also, it could generate antibiotic resistance and recolonization 
of treated sites with pathogenic bacteria is frequent [112, 113]. Hence, there is a need of new 
treatment paradigms in periodontal disease management.
Several clinical trials were conducted in order to study the effect of administration of probiot-
ics in initial treatment of periodontitis [114–117]. The bacteria most frequently used as pro-
biotic are L. reuteri (DSM 17938 + ATCC PTA 5289) [72, 118–120], Lactibacillus salivarius WB21 
[121, 122], L. reuteri (ATCC 55730 + ATCC PTA 5289) [123], L. reuteri (ATCC PTA 5289) [61], 
Streptoccus oralis KJ3 + Streptococcus uberis KJ2 + Streptoccus rattus JH145 [124] and L. rhamnosus 
SP1 [125].
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Vivekananda et al. conducted a randomized, placebo-controlled, double blind, split-mouth 
designed clinical study to evaluate the effect of L. reuteri (DSM 17938 + ATCC PTA 5289) 
lozenges with and without scaling and root planning (SRP) on clinical and microbiological 
parameters of chronic periodontitis patients. The study period was 42 days. The lozenges 
were used two times a day for 21 days, from day 21 to day 42. Thirty systemically healthy 
subjects were recruited. On day 42, plaque index, gingival index and bleeding on probing 
decreased for all treatments. However, the level of this reduction was higher in SRP + pro-
biotic, and lower, in placebo (p <0.05). Probiotic, with or without SRP, reduced significantly 
P. gingivalis, A. actinomycetemcomitans and P. intermedia [118].
Teughels et al. conducted a randomized, parallel, controlled and double blinded clinical, 
whose aim was to evaluate the effect of L. reuteri (DSM 17938 + ATCC PTA 5289, 1 × 108 
CFU)-containing lozenges as an adjunct to full mouth disinfection protocol (FMD). Thirty 
systemically healthy patients were recruited (n = 15 in each group). Clinical measurements 
and microbiological samples were collected at baseline and 3, 6, 9 and 12 months after initial 
therapy with FMD. The lozenges were used two times a day for 12 weeks. At the end of inter-
vention, i.e., 12 weeks after FMD, all clinical parameters were significantly reduced in both 
groups. In probiotic group, there was more pocket depth reduction and attachment gain (p < 
0.05). Also, there was more P. gingivalis reduction (p < 0.05) [119].
Tekce et al. and Ince et al. conducted a randomized, parallel, controlled and double blinded 
clinical trial in order to evaluate the effect of lozenges containing L. reuteri (DSM 17938 + 
ATCC PTA 5289, 1 × 108 CFU) as an adjuvant to full mouth scaling and root planning treat-
ment for chronic periodontitis. The lozenges were used two times a day for 3 weeks. Forty 
systemically healthy subjects were recruited (n = 20 in test group). Clinical measurements, 
microbiological and GCF samples were obtained at baseline and on days 21, 90, 180 and 360. 
After treatment, plaque index, gingival index, bleeding on probing and probing pocket depth 
were lower in test group at all times points (p <0.05) [120]. Attachment gain was significantly 
higher in the test group on days 90, 180 and 360 (p <0.05) [72]. Total viable cell counts and 
the proportions of obligate anaerobes in subgingival plaque were lower in test group at all 
time points (p <0.05), with the exception of day 360 [120]. Also, decreased GCF MMP-8 and 
increased TIMP-1 levels were found to be significant up to day 180 in test group (p <0.05) [72].
Shimauchi et al. and Mayanagi et al. conducted a randomized placebo-controlled clinical trial, 
whose objective was to evaluate the effect of L. salivarius (WB21, 6.7 × 108 CFU)-containing 
tablet or a placebo in treatment of mild and moderate periodontitis. The dose was three tab-
lets taken orally every day during 8 weeks. Periodontal treatment was not performed. Sixty-
six systemically healthy volunteers were recruited (n = 34 in test group). Periodontal clinical 
parameters, whole saliva samples and supra and subgingival plaque samples were obtained 
at baseline, 4 weeks, and at the end of the interventional period (8 weeks). Current smokers 
in the test group showed a significantly greater improvement of plaque index and prob-
ing pocket depth when compared with placebo group. Salivary lactoferrin level was also 
significantly decreased in the test group smokers [121]. The numerical sum of five selected 
periodontopathic bacteria and T. forsythia in subgingival plaque decreased significantly in 
test group (p <0.05) at 4 weeks of treatment [122].
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Vicario et al. conducted a randomized placebo-controlled, parallel design, double-blind clini-
cal trial. The aim was to evaluate the effect of L. reuteri (ATCC 55730 + ATCC PTA 5289, 2 × 108 
CFU)-containing lozenges in treatment of chronic periodontitis. Twenty systemically healthy 
subjects were recruited. Periodontal treatment was not performed. Subjects were advised to use 
a lozenge every day for 30 days. Clinical measurements were performed at baseline and at the 
end of interventional period. Only test group demonstrated a significant reduction in plaque 
index, bleeding on probing and pocket depth at the end of interventional period (p < 0.05) [123].
Szkaradkiewicz et al. conducted a clinical trial aimed to evaluate the pro-inflammatory cyto-
kine response in patients with chronic periodontitis administered with probiotic L. reuteri 
(ATCC PTA 5289, 1 × 108 CFU)-containing lozenges. Control group did not receive lozenges. 
All patients were treated with SRP. They recruited 38 systemically healthy subjects (n = 24 
in test group). The dose was two lozenges per day (authors did not mention the duration of 
intervention). Test group experimented a significant improvement of clinical measurements 
and a decrease in CGF levels of TNF-α, IL-1β and IL-17 (p <0.05) [61].
Laleman et al. conducted a double-blind, placebo-controlled, randomized clinical trial with 
two parallel arms in chronic periodontitis. The aim was to evaluate the adjunctive effect of 
probiotic (Streptoccus oralis KJ3 + Streptococcus uberis KJ2 + Streptoccus rattus JH145, 1 × 108 
CFU)-containing lozenges after FMD. The dose was two lozenges per day during 3 months. 
Forty-eight subjects were recruited. Clinical parameters and microbiological samples were 
collected at baseline, 4, 8, 12 and 24 weeks follow-up visit. In test group, plaque index was 
significantly lower at the 24-week evaluation (p <0.05) Also, salivary P. intermedia counts were 
significantly lower at the 12-week visit in probiotic group (p <0.05) [124].
Morales et al. conducted a double-blind placebo controlled parallel-arm randomized clinical 
trial whose objective was to evaluate the clinical effect of L. rhamnosus (SP1, 2 × 107 CFU)-
containing sachet as an adjunct to non-surgical therapy (SRP) of chronic periodontitis. 
Twenty-eight systemically healthy subject were recruited (n = 14 in test group). The dose 
was one sachet of probiotic or placebo taken orally every day during 3 months. Treatment 
involved SRP per quadrant performed with 1-week intervals in four to six sessions. A peri-
odontal supportive therapy was performed every 3 months. Clinical parameters were mea-
sured at baseline, 3, 6, 9 and 12 months follow-up visit. Both groups showed improvements in 
clinical parameters at all time points evaluated. However, there were no differences between 
groups in any visit [125, 126].
There are some systematic reviews whose aim was to explore the available clinical evidence 
on the efficacy of probiotic therapy in initial treatment of chronic periodontitis. There was a 
significant reduction in probing pocket depth, bleeding on probing, plaque index and attach-
ment gain in probiotic group [116]. In the studies where L. reuteri was selected as probiotic, 
the reduction of probing pocket depth was 1.31–1.74 mm in probiotic group and 0.49–1.39 
mm in placebo group. Also, the attachment gain was 0.99–1.39 mm in probiotic group and 
0.29–0.76 mm in placebo group [117]. Finally, the authors concluded that oral administration 
of probiotics is a safe and effective adjunct to scaling and root planning in the treatment of 
chronic periodontitis. Their adjunctive use is likely to improve diseases indices and reduce 
the need for antibiotics [116].
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The use of probiotics in supportive periodontal therapy (SPT) was reported in a clinical trial 
conducted by Iwasaki et al. The aim of this randomised, double-blind, placebo controlled 
clinical trial was to evaluate the effect of heat-killed L. plantarum L-137 on the outcome of SPT. 
Thirty-nine SPT subjects (n = 20 in test group) who completed active treatment for chronic 
periodontitis followed by SPT every 4 weeks were recruited. Subjects consumed a hard gela-
tine capsule of 50 mg of probiotic or placebo per day during 12 weeks. The SPT programmes 
and clinical examinations were performed at baseline 4, 8, and 12 weeks after start inter-
vention. Bleeding on probing and sites with pocket probing depth ≥4 mm were significantly 
reduced in both groups. In test group, there was a significantly greater probing pocket depth 
(PPD) reduction in teeth with sites with PPD ≥ 4 mm at week 12 (p <0.05). This result indicates 
that daily intake of probiotic may be useful in SPT [127].
6. Conclusions
Oral diseases are a recognized public health problem worldwide [128, 129]. Dental caries, peri-
odontitis and oral cancer, among other oral diseases, currently occupy the health agenda, seek-
ing to establish policies that, when integrated with other health intervention programs, will 
impact the oral health of our population. Along with the economic impact on governments 
and individuals [130], a higher cost is added in terms of pain, discomfort, social and functional 
limitations, and time lost and absenteeism in schools and workplaces [131, 132].
The goals of periodontal therapy are to reduce probing pocket depth, to gain attachment level 
and to reduce bleeding on probing suppuration. A new microbial community is needed in 
order to achieve the clinical results [109]. Therefore, with the aim of potentiating the effects 
of periodontal treatment, other protocols, such as the association of mechanical debridement 
with systemic antibiotics, have been used successfully in the treatment of periodontal dis-
eases. The problems of antibiotics are in association with the elimination of the entire micro-
flora, irrespective of their pathogenicity, and the emergence of antibiotic resistance; the shift 
towards a less pathogenic microbiota is only temporary with a frequent recolonization of 
treated sites with pathogenic bacteria; and the temporary use of antibiotics locally or systemi-
cally, does not really improve the long-term effect of periodontal therapy.
Considering the beneficial effects of probiotics, this therapy could serve as a useful adjunct 
or alternative to periodontal treatment. The use of probiotics in oral care applications is gain-
ing momentum [118]. There is increasing evidence that the use of existing probiotic strains 
can deliver oral health benefits. Therefore, proposing a treatment involving the non-surgical 
treatment plus probiotic intake may result in better regulation of bacterial plaque and thus 
contribute to a successful periodontal treatment, and they can also exert effects on modulating 
immunological parameters.
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